SOCRA - Society of Clinical Research Associates Investigational Product Management Questions and Answers 1 — Questions and Answers
Question 1: An investigational drug must be stored between 2°C and 8°C. A temperature log for the dedicated refrigerator shows a reading of 10°C for a period of four hours. What is the MOST appropriate immediate action for the site staff to take?
- Quarantine the affected drug, notify the sponsor, and await instructions on disposition. (Correct answer)
- Discard the drug immediately and document it as destroyed in the accountability record.
- Continue dispensing the drug as the excursion was minor and unlikely to affect its stability.
- Recalibrate the thermometer and inform the monitor at the next scheduled site visit.
Correct answer: Quarantine the affected drug, notify the sponsor, and await instructions on disposition.
Patient safety is paramount. When a temperature excursion occurs, the product's stability and efficacy may be compromised. The correct procedure is to immediately quarantine the affected product to prevent it from being dispensed, notify the sponsor who has the stability data to assess the impact of the excursion, and wait for their official determination on whether the product can still be used or must be destroyed.
Question 2: A clinical research coordinator performs a routine inventory of the investigational product and discovers a discrepancy between the dispensing log and the physical count. What is the MOST appropriate first step?
- Order a new shipment from the sponsor to replace the missing product.
- Immediately quarantine the remaining stock, document the discrepancy, and notify the Principal Investigator and sponsor. (Correct answer)
- Inform the monitor at the next scheduled visit.
- Assume a documentation error occurred and adjust the dispensing log to match the physical count.
Correct answer: Immediately quarantine the remaining stock, document the discrepancy, and notify the Principal Investigator and sponsor.
According to GCP principles, any discrepancy in investigational product accountability must be addressed immediately to ensure patient safety and data integrity. The first step is to secure the remaining product (quarantine), thoroughly document the finding, and promptly report it to the Principal Investigator and the sponsor. This allows for a timely investigation into the cause of the discrepancy.
Question 3: Which of the following is NOT a required element on the label of an investigational product according to 21 CFR 312.6?
- The protocol code or study number.
- A statement such as 'Caution: New Drug—Limited by Federal (or United States) law to investigational use.'
- The name and address of the Principal Investigator. (Correct answer)
- The name or identification code of the drug.
Correct answer: The name and address of the Principal Investigator.
21 CFR 312.6 specifies the labeling requirements for an investigational new drug. It requires a statement indicating the product is for investigational use. While GCP guidelines often lead to the inclusion of the protocol number, drug identifier, and sponsor information, the regulation does not explicitly require the Principal Investigator's name and address to be on the immediate product label; the sponsor's name and address is the standard requirement.
Question 4: At the conclusion of a clinical trial, what is the required procedure for handling unused investigational product at the clinical site?
- The site should destroy all unused product and notify the IRB of the destruction.
- The Principal Investigator may use the remaining product for compassionate use cases.
- The unused product should be returned to the site's general pharmacy stock for dispensing.
- The site must follow the sponsor's instructions for the return or authorized destruction of the unused product. (Correct answer)
Correct answer: The site must follow the sponsor's instructions for the return or authorized destruction of the unused product.
The sponsor is the owner of the investigational product and is ultimately responsible for its final disposition. According to 21 CFR 312.59 and ICH GCP, the site must reconcile all investigational product and then follow the sponsor's specific written instructions for either returning the unused supply or destroying it on-site. All actions must be thoroughly documented in the accountability records.
Question 5: A participant in a double-blinded trial presents to an outside emergency room with a life-threatening condition. The treating physician believes knowing the treatment assignment is critical for patient care. According to standard procedures, who holds the primary authority and mechanism to grant an emergency unblinding request?
- The Sponsor or their designated representative (e.g., medical monitor). (Correct answer)
- The Chairperson of the Institutional Review Board (IRB).
- The lead research pharmacist at the investigational site.
- The Principal Investigator, who can unblind at their sole discretion.
Correct answer: The Sponsor or their designated representative (e.g., medical monitor).
The sponsor holds the randomization code for the entire study and is responsible for establishing and maintaining the procedure for emergency unblinding. While the PI would facilitate the request, the formal process requires contacting the sponsor (or a 24/7 service designated by them) who can officially break the blind for a specific participant when it is medically necessary. This ensures the integrity of the overall study is protected while prioritizing subject safety.
Question 6: Which of the following documents is the primary, comprehensive record used at a clinical site to track the investigational product from receipt to its final disposition?
- The bill of lading from the shipping courier.
- The subject's individual case report forms.
- The Investigational Product Accountability Log. (Correct answer)
- The Investigator's Brochure.
Correct answer: The Investigational Product Accountability Log.
The Investigational Product Accountability Log is the central and essential document specifically designed to track the entire lifecycle of the product at the site. It records dates, quantities, batch numbers, expiration dates, and details of every unit received, dispensed to subjects, returned by subjects, and ultimately returned to the sponsor or destroyed.
SOCRA - Society of Clinical Research Associates Investigational Product Management Questions and Answers 1
An investigational drug must be stored between 2°C and 8°C.
A temperature log for the dedicated refrigerator shows a reading of 10°C for a period of four hours.
What is the MOST appropriate immediate action for the site staff to take?